Besides targeting immune cells, clinical trial for use of humanized IgG1 anti-PD-L1 mAb atezolizumab along with bevacizumab (mAb against VEGF) is currently enrolling HPV or EBV-associated HNSCC patients (NCT03074513). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.